Testosterone Treatment in Multiple Sclerosis

_A Pilot Study_

Nancy L. Sicotte, MD; Barbara S. Giesser, MD; Vinita Tandon, MD; Ricki Klutch, RN; Barbara Steiner, RN; Ann E. Drain, BS; David W. Shattuck, PhD; Laura Hull, BS; He-Jing Wang, PhD; Robert M. Elashoff, PhD; Ronald S. Swerdloff, MD; Rhonda R. Voskuhl, MD

**Objective:** To study the effect of testosterone supplementation on men with multiple sclerosis (MS).

**Design, Setting, and Participants:** Men are less susceptible to many autoimmune diseases, including MS. Possible causes for this include sex hormones and/or sex chromosome effects. Testosterone treatment ameliorates experimental allergic encephalomyelitis, an animal model of MS, but the effect of testosterone supplementation on men with MS is not known. Therefore, 10 men with relapsing-remitting MS were studied using a crossover design whereby each patient served as his own control. There was a 6-month pre-treatment period followed by a 12-month period of daily treatment with 10 g of the gel containing 100 mg of testosterone.

**Main Outcome Measures:** Clinical measures of disability and cognition (the Multiple Sclerosis Functional Composite and the 7/24 Spatial Recall Test) and monthly magnetic resonance imaging measures of enhancing lesion activity and whole brain volumes.

**Results:** One year of treatment with testosterone gel was associated with improvement in cognitive performance (P = .008) and a slowing of brain atrophy (P < .001). There was no significant effect of testosterone treatment on gadolinium-enhancing lesion numbers (P = .31) or volumes (P = .94). Lean body mass (muscle mass) was increased (P = .02).

**Conclusion:** These exploratory findings suggest that testosterone treatment is safe and well tolerated and has potential neuroprotective effects in men with relapsing-remitting MS.

**Trial Information:** clinicaltrials.gov Identifier: NCT00405353

_Arch Neurol._ 2007;64:683-688

During reproductive ages, there is a distinct female preponderance of autoimmune diseases, including multiple sclerosis (MS).1 Sex hormones and/or sex chromosomes may be responsible for this enhanced susceptibility. The female-to-male ratio is greater in patients presenting with MS before the age of 20 years (3.2:1.0) compared with the ratio in the population with MS as a whole (2:1).2 In males, the onset of MS tends to be later in life (30s-40s), as bioavailable testosterone levels decline.3

Testosterone has a protective effect in many animal models of autoimmune disease, including multiple sclerosis (MS).1 Sex hormones and/or sex chromosomes may be responsible for this enhanced susceptibility. The female-to-male ratio is greater in patients presenting with MS before the age of 20 years (3.2:1.0) compared with the ratio in the population with MS as a whole (2:1).2 In males, the onset of MS tends to be later in life (30s-40s), as bioavailable testosterone levels decline.3

Testosterone has a protective effect in many animal models of autoimmune disease, including multiple sclerosis (MS).1 Sex hormones and/or sex chromosomes may be responsible for this enhanced susceptibility. The female-to-male ratio is greater in patients presenting with MS before the age of 20 years (3.2:1.0) compared with the ratio in the population with MS as a whole (2:1).2 In males, the onset of MS tends to be later in life (30s-40s), as bioavailable testosterone levels decline.3

In addition to being immunomodulatory, testosterone has been shown to be neuroprotective in several models of neurodegenerative disease.10 In humans, it may improve cognitive function in hypogonadal healthy men,12 and in men with Alzheimer disease.13 In light of the well-described neuroprotective effects of estrogens,14 mechanisms underlying the neuroprotective effects of testosterone treatment may involve its conversion to estrogen by aromatase.15 On the other hand, testosterone treatment has been shown to be toxic to cultured oligodendrocytes.10

**Author Affiliations:** Division of Brain Mapping (Dr Sicotte and Ms Drain), Departments of Neurology (Drs Sicotte, Giesser, and Voskuhl, and Ms Klutch and Drain) and Biomathematics (Drs Wang and Elashoff), and Laboratory of Neuro Imaging (Dr Shattuck), The David Geffen School of Medicine at UCLA, Los Angeles, Calif; and Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, Calif (Drs Tandon and Swerdloff and Ms Steiner and Hull).
Thus, it is unknown whether testosterone treatment would be beneficial or detrimental in those with MS.

Previously, neuroimaging studies in 413 subjects, comparing women and men with MS, have been conducted to reveal some insights into the effect of testosterone in MS. Men had fewer contrast-enhancing lesions than women, but had a higher likelihood for them to evolve into T1-weighted “black holes.” These data were consistent with the observation that men are less likely to develop MS, but when they do, it tends to be more severe clinically. In a follow-up study of 35 women and 25 men with relapsing-remitting MS (RRMS), the finding of fewer enhancing lesions in men was confirmed, but the increased likelihood for lesions to evolve into T1-weighted black holes in men was not, perhaps because of the smaller sample size.

Finally, testosterone treatment is frequently used to improve muscle mass and bone mineral density in elderly hypogonadal men, and in men with various chronic diseases, but the effects in MS are not known. Thus, to investigate possible effects of testosterone treatment in those with MS, testosterone was administered via transdermal gel application (AndroGel; Solvay Pharmaceuticals, Inc, Marietta, Ga) to men with RRMS to investigate safety and tolerability, as well as effects on clinical disability and brain magnetic resonance imaging (MRI).

### METHODS

Men aged 18 to 65 years who met the Poser criteria for clinically definite RRMS, were not receiving disease-modifying treatment, and had an Expanded Disability Status Scale score of 0 to 3.0 were studied. Subjects had to have at least 1 clinical relapse (worsening of a preexisting symptom or appearance of a new symptom, each over 0-3 days) or the appearance of at least 1 greater than 3-mm gadolinium-enhancing lesion on brain MRI during the preceding 2 years. The protocol was approved by the University of California, Los Angeles (ULCA) Human Subjects Protection Committee and the institutional review board of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.

Given the small sample size of this initial pilot study, each subject served as his own control, thereby minimizing the effect of interindividual heterogeneity of disease, as described. Serum testosterone levels were measured by a radioimmunoassay kit from Diagnostic Product Corporation, Los Angeles, Calif. The limit of quantitation of serum testosterone measured by this assay was 12.4 ng/dL (0.43 nmol/L). All results less than this value were reported as 12.4 ng/dL. The mean accuracy (recovery) of the testosterone assay, determined by spiking corticosteroid-free serum with varying amounts of testosterone (25.9-1613.8 ng/dL [0.9-56.0 nmol/L]), was 104% (range, 95%-114%). The intra-assay and interassay coefficients of the testosterone assay were 4.0% and 5.8%, respectively, at the healthy adult male range, which in our laboratory was 277.2 to 945.5 ng/dL (9.62-32.81 nmol/L).

Finally, testosterone treatment is frequently used to improve muscle mass and bone mineral density in elderly hypogonadal men, and in men with various chronic diseases, but the effects in MS are not known. Thus, to investigate possible effects of testosterone treatment in those with MS, testosterone was administered via transdermal gel application (AndroGel; Solvay Pharmaceuticals, Inc, Marietta, Ga) to men with RRMS to investigate safety and tolerability, as well as effects on clinical disability and brain magnetic resonance imaging (MRI).

### Table. Testosterone Study Design

<table>
<thead>
<tr>
<th>Variable</th>
<th>Screening (Month –6)</th>
<th>Pretreatment (Months –5 to 0)</th>
<th>Treatment (Months 1-12)</th>
<th>Exit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical assessments: EDSS and MSFC (includes the 25-ft timed walk, the 9-Hole Peg Test, and the PASAT)</td>
<td>Performed</td>
<td>Months –3 and 0</td>
<td>Months 3, 6, 9, and 12</td>
<td>Not performed</td>
</tr>
<tr>
<td>Other cognitive measures: 7/24 Spatial Recall Test</td>
<td>Not performed</td>
<td>Month 0</td>
<td>Months 6 and 12</td>
<td>Not performed</td>
</tr>
<tr>
<td>Serum measures: CBC count, SMA-12, PSA, lipids, prostate and tests examination, and testosterone levels*</td>
<td>Performed</td>
<td>Months –3 and 0</td>
<td>Months 3, 6, 9, and 12</td>
<td>Performed</td>
</tr>
<tr>
<td>Cerebral MRI</td>
<td>Performed</td>
<td>Monthly</td>
<td>Monthly 6 and 12</td>
<td>Not performed</td>
</tr>
<tr>
<td>Testosterone pharmacokinetics, DEXA bone scan, and muscle mass determination</td>
<td>Not performed</td>
<td>Month 0</td>
<td>Not performed</td>
<td>Not performed</td>
</tr>
</tbody>
</table>

*Serum testosterone levels were measured by a radioimmunoassay kit from Diagnostic Product Corporation, Los Angeles, Calif. The limit of quantitation of serum testosterone measured by this assay was 12.4 ng/dL (0.43 nmol/L). All results less than this value were reported as 12.4 ng/dL. The mean accuracy (recovery) of the testosterone assay, determined by spiking corticosteroid-free serum with varying amounts of testosterone (25.9-1613.8 ng/dL [0.9-56.0 nmol/L]), was 104% (range, 95%-114%). The intra-assay and interassay coefficients of the testosterone assay were 4.0% and 5.8%, respectively, at the healthy adult male range, which in our laboratory was 277.2 to 945.5 ng/dL (9.62-32.81 nmol/L).
Eleven subjects with RRMS were enrolled in the study. One subject discontinued participation after moving out of the area at study month −4, and no data from this subject were included in the analysis. The mean age of the subjects was 46 (range, 29-61) years. The median disease duration was 12.5 (range, 0.5-25.0) years. The median Expanded Disability Status Scale score was 2.0 (range, 1.5-2.5).

At baseline, all subjects had testosterone levels in the lower range of normal, with a mean of 493 ng/dL (17.1 nmol/L) (range, 321-732 ng/dL [11.1-25.4 nmol/L]). During daily treatment with 10 g of the gel containing 100 mg of testosterone, serum testosterone levels increased 50% on average to the higher range of normal (Figure 1).

Lean body mass (muscle mass) increased significantly during treatment, with a mean increase of 1.7 kg at month 12 of treatment compared with pretreatment levels (P=.02). Hip and spine bone density, as measured by the dual energy x-ray absorptiometry scan, were normal at baseline and remained unchanged during the study.

There were no subjective reports of adverse effects and no significant abnormalities in any blood test results. Prostate examination results were stable throughout the study. One subject necessitated placement of a cardiac stent, but this was not thought to be drug related because he had preexisting risk factors for coronary artery disease.

Scores from the Paced Auditory Serial Addition Task (PASAT) component of the Multiple Sclerosis Functional Composite remained stable during the first 6 months of treatment (months 3 and 6), trended upward after 9 months, and were significantly improved by month 12 of treatment (Figure 2). During the baseline pre-treatment phase, there was clearly a practice effect, as previously described.25-27 Thus, to avoid the confound of this practice effect in interpreting the effect of treatment, PASAT performance during months 9 and 12 of testosterone treatment, before the practice effect, was compared with scores during treatment. While there were no effects of testosterone treatment within the first 6 months of treatment (months 3 and 6), a trend for improvement began at treatment month 9, which became significant at month 12. The improvement was significant in the entire group of 10 subjects (P=.008). *Nonparametric P values based on Wilcoxon signed rank tests.

**RESULTS**

![Figure 1](image_url) **Figure 1.** Testosterone pharmacokinetics assessed over 24 hours during pretreatment baseline and at month 12 of treatment. Serum testosterone levels were determined at multiple time points throughout a 24-hour period, twice during the study. Compared with baseline measures that were obtained during the pretreatment period, which reflect the natural fluctuations of endogenous testosterone before treatment (month 0), the testosterone levels measured at month 12 of treatment were increased by approximately 50% by area under the curve analysis. For the month 12 treatment data, the first measure recorded at time 0 was obtained before the testosterone gel (AndroGel; Solvay Pharmaceuticals, Inc, Marietta, Ga) was applied. The dashed lines indicate the range of healthy adult male testosterone levels.

![Figure 2](image_url) **Figure 2.** Paced Auditory Serial Addition Task (PASAT) cognitive test scores improved with testosterone treatment in men with relapsing-remitting multiple sclerosis. The PASAT cognitive tests were administered every 3 months (pretreatment months −6, −3, and 0 and treatment months 3, 6, 9, and 12). As previously reported, “practice effects” resulted in PASAT performance improvement initially during baseline, which stabilized by the third trial.25 month 0 in our study. Accordingly, to evaluate the effect of testosterone treatment on PASAT performance, only scores at pretreatment month 0 (not months −6 and −3) were used to compare with scores during treatment. While there were no effects of testosterone treatment within the first 6 months of treatment (months 3 and 6), a trend for improvement began at treatment month 9, which became significant at month 12. The improvement was significant in the entire group of 10 subjects (P=.008). *Nonparametric P values based on Wilcoxon signed rank tests.
P = .94). T2-weighted lesion volumes were not significantly different comparing the observation and treatment periods (mean T2-weighted volume, 11.78 vs 12.51 cm³; P = .21).

At study onset, the mean normalized whole brain volume was 0.82 (range, 0.78-0.84) and was negatively correlated with age (P = .05); however, there was no relationship between baseline brain volumes and baseline testosterone levels (r = 0.18). During the first 9 months of the study, brain volumes decreased at an annualized rate of −0.81% (P < .001, compared with no change). In contrast, no significant atrophy occurred during the last 9 months of treatment, when the annualized rate of atrophy slowed to −0.26% (P = .10). This difference represents a 67% reduction in the rate of brain atrophy after the initiation of testosterone treatment. Circles indicate individual results; solid line, Loess regression fit of the data; and dashed line, extrapolated atrophy rate based on the initial 9-month period.

**Figure 3.** Brain volume loss stabilized during testosterone treatment. The percentage change in normalized brain volumes is shown during the baseline and treatment periods in men with relapsing multiple sclerosis. A steady decline in brain volume was observed during the 6-month pretreatment period (months −5 to 0), continuing into the first 3 months of treatment, before stabilizing. Slope change during this initial 9 months corresponded to a −0.81% annualized atrophy rate (P < .001, compared with no change). In contrast, no significant atrophy occurred during the last 9 months of treatment, when the annualized rate of atrophy slowed to −0.26% (P = .10). This difference represents a 67% reduction in the rate of brain atrophy after the initiation of testosterone treatment. Circles indicate individual results; solid line, Loess regression fit of the data; and dashed line, extrapolated atrophy rate based on the initial 9-month period.

The PASAT component of the Multiple Sclerosis Functional Composite showed significant improvement at month 12 of testosterone treatment. Practice effects are common when the PASAT is administered serially. Previous reports demonstrated that PASAT performance stabilizes after the third session, and this effect was evident when between-session timing was as brief as 1 week or as long as 6 months. In our study, PASAT performance was tested every 3 months and performance also stabilized after 3 trials, with these 3 trials all in the 6-month pretreatment baseline period. Subsequently, PASAT performance remained unchanged for the first 6 months of testosterone treatment. Then, a gradual improvement in performance was observed during the last 6 months of treatment, reaching significance at month 12. While it is theoretically possible that PASAT improvement at 9 and 12 months of treatment could reflect a second wave of practice effects, to our knowledge this has never been previously reported in placebo-treated arms of clinical trials, including those involving large cohorts of patients with MS followed up for up to 2 years.20 Our observed improvement in PASAT performance, combined with trends for improvements in the 7/24 Spatial Recall Test, is consistent with previous re-

This is a small exploratory study of treatment of male patients with RRMS with testosterone gel for 1 year. A crossover design, using a within-arm comparison of pretreatment to treatment, was used to reduce the effect of disease heterogeneity given the small sample size, as previously described.22

The PASAT component of the Multiple Sclerosis Functional Composite showed significant improvement at month 12 of testosterone treatment. Practice effects are common when the PASAT is administered serially. Previous reports demonstrated that PASAT performance stabilizes after the third session, and this effect was evident when between-session timing was as brief as 1 week or as long as 6 months. In our study, PASAT performance was tested every 3 months and performance also stabilized after 3 trials, with these 3 trials all in the 6-month pretreatment baseline period. Subsequently, PASAT performance remained unchanged for the first 6 months of testosterone treatment. Then, a gradual improvement in performance was observed during the last 6 months of treatment, reaching significance at month 12. While it is theoretically possible that PASAT improvement at 9 and 12 months of treatment could reflect a second wave of practice effects, to our knowledge this has never been previously reported in placebo-treated arms of clinical trials, including those involving large cohorts of patients with MS followed up for up to 2 years. Our observed improvement in PASAT performance, combined with trends for improvements in the 7/24 Spatial Recall Test, is consistent with previous re-
ports of testosterone-mediated improvements in working and spatial memory in healthy nonhypogonadal elderly men. Interestingly, the timing of these cognitive improvements coincided with a slowing of brain atrophy on MRI.

Measures of inflammatory activity on MRI did not decrease significantly after treatment with testosterone, which may be because of the relatively low levels of inflammatory activity present at baseline. Despite the fact that inclusion criteria required either a relapse or enhancing lesion activity in the 2 years prior to enrollment, the exclusion of subjects taking disease-modifying treatments likely created a selection bias toward subjects with a relatively milder clinical disease and less inflammatory activity on MRI. Thus, in this subject group, we can only conclude that testosterone treatment did not significantly increase inflammatory activity on otherwise relatively quiescent MRIs.

Previous studies in noninflammatory conditions have shown that testosterone can affect brain volumes independent of effects on inflammation. Men with Klinefelter syndrome have androgen deficiency and smaller left temporal lobe volumes, and testosterone supplementation during development led to larger gray matter volumes in the left temporal lobe and improved verbal fluency scores in these patients. In our study, brain atrophy rates were determined by dividing the 18-month study period into 9-month intervals, which includes the first 3 months of treatment with the baseline period of observation. This approach is consistent with other reports assessing the effects of treatment on brain atrophy, and takes into account the likelihood that neuroprotective effects are unlikely to be evident until several months of treatment have occurred. The mean annualized brain atrophy rate of −0.81% observed during the first 9 months of this study was consistent with previous rates observed in patients with MS. During the last 9 months of treatment, the rate of atrophy slowed to −0.26%, representing a decrease of 67%. Because the protective effect of testosterone treatment on brain atrophy was observed in the absence of an appreciable anti-inflammatory effect, this protection may not be limited to MS, but may be applicable to those with noninflammatory neurodegenerative diseases.

As is the case with any initial pilot clinical trial, conclusions from our study must be made with caution primarily because of the small sample size. Also, findings in our study may or may not be applicable to subjects with MS with more aggressive disease. Overall, in this first trial of testosterone treatment in men with RRMS, the treatment was shown to be safe and well tolerated, and led to increases in lean body mass. In addition, exploratory findings reported herein suggest a possible neuroprotective effect of testosterone treatment in men, which warrants further investigation.

Accepted for Publication: December 14, 2006.

Correspondence: Rhonda R. Voskuhl, MD, Department of Neurology, The David Geffen School of Medicine at UCLA, Neuroscience Research Bldg, Room 475D, 635 Charles Young Dr S, Los Angeles, CA 90095 (rvoskuhl@ucla.edu).

Author Contributions: Study concept and design: Sicotte, Steiner, Swerdloff, and Voskuhl. Acquisition of data: Sicotte, Giesser, Tandon, Klutch, Steiner, Drain, Hull, and Voskuhl. Analysis and interpretation of data: Sicotte, Tandon, Shattuck, Wang, Elashoff, Swerdloff, and Voskuhl. Drafting of the manuscript: Sicotte, Giesser, Hull, Wang, and Voskuhl. Critical revision of the manuscript for important intellectual content: Sicotte, Giesser, Tandon, Klutch, Steiner, Drain, Shattuck, Elashoff, Swerdloff, and Voskuhl. Statistical analysis: Wang and Elashoff. Obtained funding: Sicotte and Voskuhl. Administrative, technical, and material support: Giesser, Tandon, Klutch, Steiner, Drain, Shattuck, Hull, and Swerdloff. Study supervision: Sicotte, Giesser, Steiner, Swerdloff, and Voskuhl.

Financial Disclosure: None reported.

Funding/Support: This study was supported by grants RG3239 and JF2107 from the National Multiple Sclerosis Society; grant MO1 RR00425 from the General Clinical Research Centers at Harbor-UCLA Medical Center; the Sherak Family Foundation; and the Skirball Foundation.

REFERENCES


---

**Call for Papers**

The Clinical Trials section is actively recruiting papers and clinical trials are a priority interest with our Editorial Board. Investigator-initiated, placebo-controlled, double-blind clinical trials are preferred. Open-label studies that are properly controlled will also be considered. The clinical trial must be registered with a recognized clinical trials Web site and the site and registration number should appear on the front page of the paper. Clinical trials that are industry supported must include the statement that all data are made available to the investigators by the sponsor, that the investigators have the right to publish all data, and that the investigators have included a statistical analysis that is independent of any statistical analyses done by the industry sponsor. We encourage submission of clinical trials papers and will have them reviewed in an efficient manner.